Study of information submitted by drug companies to licensing authorities
about
Reporting bias in medical research - a narrative reviewPublication of clinical trials supporting successful new drug applications: a literature analysisAmphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patientsThe safety of acupuncture during pregnancy: a systematic reviewEffectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug AdministrationSystematic review of the empirical evidence of study publication bias and outcome reporting bias - an updated reviewOutcome reporting bias in randomized trials funded by the Canadian Institutes of Health ResearchReporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentationReporting of Adverse Events in Published and Unpublished Studies of Health Care Interventions: A Systematic ReviewNon-Publication Is Common among Phase 1, Single-Center, Not Prospectively Registered, or Early Terminated Clinical Drug TrialsSystematic review of the empirical evidence of study publication bias and outcome reporting biasAmphotericin B vs fluconazole for controlling fungal infections in neutropenic cancer patients.Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols.Bias, spin, and misreporting: time for full access to trial protocols and results.Innovation and cross-fertilization in systematic reviews and meta-analysis: The influence of women investigators.Non interventional drug studies in oncology: Why we need them?Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review.Occurrence and determinants of selective reporting of clinical drug trials: design of an inception cohort studyClinical and economic burden of adverse drug reactionsThe evolution of assessing bias in Cochrane systematic reviews of interventions: celebrating methodological contributions of the Cochrane Collaboration.Toward standardized reporting of drug interactions: the READI checklist for anecdotal reports.The application of clinical toxicology.Report on a pilot project to introduce a publications officer.How good are articles on adverse drug reactions?Is the introduction of drugs into Canada unduly delayed?Misconduct in medical research.Clinical trial registration at Tobacco Control.From optimism to disillusion about commitment to transparency in the medico-industrial complex.Recognizing, investigating and dealing with incomplete and biased reporting of clinical research: from Francis Bacon to the WHO.A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports
P2860
Q21203744-E1457578-1473-4825-9F91-AFDF428AD8B5Q21563410-FA39DDC7-44AF-4D6F-B080-B4D6A8DEFFABQ24193785-4527A4AC-71B0-4319-A911-7AD0EF93B12AQ24561823-75D9041C-79C3-4BA7-929A-F8FB0846A67EQ24633044-A7342FFE-EC22-4994-88C1-601040C93FD0Q26851424-899AE320-D642-41D6-A69D-30F45292AD70Q28285027-44EF9BF2-B42E-439F-ADC1-D69CF13F26BCQ28474127-F5E4B74B-7675-485E-B73D-57B2D9B48C2CQ28554247-C42FB3C8-0E5A-45B3-BB5C-1C2D717A1856Q28555016-2E94343E-FE70-4AC3-9D39-9B141D5AA521Q29619094-1E816DC6-3E80-4B9C-96AD-3A06D062A6BEQ30887333-43CBF4BE-6809-4110-ADB1-A85CA4A82A1DQ33389750-B32EAE93-2C8C-4E24-8C95-7EF708142A49Q33391502-56239A66-1960-4214-A065-24D6A4D5D87FQ34481673-CB906654-0774-47A7-BB5D-930AC4F89988Q34595535-9908B897-2CB7-4E15-B228-F56A27D1C3F6Q35082900-AB800820-A5CA-4A31-A8A1-3F8BA84E1F20Q35844255-9E869947-990E-4A62-9E10-AFECADD7AA8AQ37369674-032829E4-083D-4623-B11F-FEB5A56EAE02Q38141169-4964B733-AC52-4194-BAF4-C9C6CF4EEABEQ38505127-9D69CAD7-35AC-48A9-8313-ABF5DEC9087EQ39673589-A4485E6A-782E-4B85-8F04-8B429952AF2DQ40690439-C3B3BAFA-5AC3-4164-8A27-20F79BA91556Q41225079-33094DC1-2CCD-4361-A8D8-9B989D24BAE0Q43117570-C65632B6-B1F3-4AAD-8FD8-A3D4C71FA084Q44578209-7D903C75-5C80-434C-8770-EB53A198E53CQ46584339-59B34076-3C84-46A4-B644-5CB65FB00F0EQ50932566-9CD8B3EB-3C9A-4DCA-A789-BCBCF4B3D763Q55055406-713ACE84-1472-4CB9-AE2B-33F89C28E535Q57412712-3F76BBD5-A9E1-4A86-90C2-432763D8528C
P2860
Study of information submitted by drug companies to licensing authorities
description
1980 nî lūn-bûn
@nan
1980 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1980 թվականի մարտին հրատարակված գիտական հոդված
@hy
1980年の論文
@ja
1980年論文
@yue
1980年論文
@zh-hant
1980年論文
@zh-hk
1980年論文
@zh-mo
1980年論文
@zh-tw
1980年论文
@wuu
name
Study of information submitted by drug companies to licensing authorities
@ast
Study of information submitted by drug companies to licensing authorities
@en
Study of information submitted by drug companies to licensing authorities
@nl
type
label
Study of information submitted by drug companies to licensing authorities
@ast
Study of information submitted by drug companies to licensing authorities
@en
Study of information submitted by drug companies to licensing authorities
@nl
prefLabel
Study of information submitted by drug companies to licensing authorities
@ast
Study of information submitted by drug companies to licensing authorities
@en
Study of information submitted by drug companies to licensing authorities
@nl
P3181
P356
P1433
P1476
Study of information submitted by drug companies to licensing authorities
@en
P2093
E Hemminki
P3181
P356
10.1136/BMJ.280.6217.833
P407
P577
1980-03-22T00:00:00Z